Laborecom Therapeutics is a Chicago-based biotech developing LBRC-101, a first-in-class peptide therapeutic that prevents cancer metastasis by blocking the process tumor cells use to escape the bloodstream and colonize distant organs. This process— transendothelial migration — is an essential part of the metastastic cascade across multiple solid tumor types including breast, lung, and pancreatic cancer.

LBRC-101 has received NIH SBIR Phase I funding, validating the underlying biology of the LBRC pathway